Back to School: How biopharma can reboot drug development. Access exclusive analysis here
LDAKA (La Jolla, Calif.) reported that Lidakol, which inhibits viral
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury